Competition isn’t enough: Medicare still overpays for abiraterone
Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector
Published online on April 16, 2026
Abstract
Journal of Generic Medicines, Ahead of Print.
Following the 2018 patent expiration of abiraterone, a hormonal therapy for prostate cancer, the drug experienced a substantial influx of generic manufacturers and a marked decline in gross list prices. Using Medicare Part D reimbursement (gross pricing) ...
Following the 2018 patent expiration of abiraterone, a hormonal therapy for prostate cancer, the drug experienced a substantial influx of generic manufacturers and a marked decline in gross list prices. Using Medicare Part D reimbursement (gross pricing) ...